Agathe Molimard, Frantz Foissac, Naïm Bouazza, Inès Gana, Sihem Benaboud, Léo Froelicher, Déborah Hirt, Saïk Urien, Isabelle Desguerre, Jean-Marc Treluyer, Nicole Chemaly, Rima Nabbout
AIMS: Vigabatrin is an antiepileptic drug used to treat some forms of severe epilepsy in children. The main adverse effect is ocular toxicity, which is related to the cumulative dose. The aim of the study is to identify an acceptable exposure range, both through the development of a population pharmacokinetic model of vigabatrin in children enabling us to calculate patient exposure and through the study of therapeutic response. METHODS: We performed a retrospective study including children with epilepsy followed at Necker-Enfants Malades hospital who had a vigabatrin assay between January 2019 and January 2022...
April 25, 2024: British Journal of Clinical Pharmacology